Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis.

Francia G, Shaked Y, Hashimoto K, Sun J, Yin M, Cesta C, Xu P, Man S, Hackl C, Stewart J, Uhlik M, Dantzig AH, Foster FS, Kerbel RS. Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis. Mol Cancer Ther. 2012 Mar; 11(3):680-9.

View in: PubMed

subject areas

Administration, Oral
Animals
Antimetabolites, Antineoplastic
Blood Vessels
Cell Line, Tumor
Deoxycytidine
Dose-Response Relationship, Drug
Endothelial Cells
Female
Humans
Mice
Mice, Inbred BALB C
Mice, SCID
Neoplasms
Neovascularization, Pathologic
Prodrugs
Tumor Burden
Xenograft Model Antitumor Assays

authors with profiles

Giulio Francia

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support